Direct cost analyses of palivizumab treatment in a cohort of at-risk children: Evidence from the North Carolina Medicaid Program

Pediatrics

Volumn 114, Issue 6, 2004, Pages 1612-1619

  Wegner, Steven ^a,b   Vann, Julie Jacobson ^a   Liu, Gordon ^c   Byrns, Patricia ^b   Cypra, Clement ^d   Campbell, William ^c   Stiles, Alan ^b  

^a AccessCare   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d IL   (United States)

Author keywords

Bronchiolitis; Cost analysis; Palivizumab; Prophylaxis; Respiratory syncytial virus; Synagis

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

AMBULATORY CARE; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEATH; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SAMPLE SIZE; SEASON; TREATMENT OUTCOME; UNITED STATES; BRONCHIOLITIS; COST CONTROL; ECONOMICS; EPIDEMIOLOGY; MORTALITY; NEWBORN; PREMATURITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STATISTICAL MODEL; STATISTICS; UTILIZATION REVIEW; VIROLOGY; VIRUS INFECTION;

AMBULATORY CARE; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BRONCHIOLITIS; COHORT STUDIES; COST SAVINGS; COST-BENEFIT ANALYSIS; DIRECT SERVICE COSTS; HEALTH CARE SURVEYS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MEDICAID; MODELS, ECONOMIC; NORTH CAROLINA; REGRESSION ANALYSIS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 16644380953     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-0959     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention. Bronchiolitis-associated outpatient visits and hospitalizations among American Indian and Alaskan Native children - United States, 1990-2000. MMWR Morb Mortal Wkly Rep. 2003;52:707-710
2. Centers for Disease Control and Prevention, National Center for Infectious Diseases. Respiratory Syncytial Virus; 2004. Available at: www.cdc.gov/ncidod/aip/research/rsv.html. Accessed June 10, 2004
3. Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865-870
4. Sorrentino M, Powers T, and the Palivizumab Outcomes Study Group. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Pediatr Infect Dis J. 2000;19:1068-1071
5. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282:1440-1446
6. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537
7. Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003
8. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants. Arch Pediatr Adolesc Med. 2002;156:1034-1041
9. Howard TS, Hoffman LH, Stang PE, Simoes EA. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J Pediatr. 2000;137:227-232
10. Shireman TI, Braman KS. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas Medicaid's high-risk children. Arch Pediatr Adolesc Med. 2002;156:1251-1255
11. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Policy statement: prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV IGIV (RE9839). Pediatrics. 1998;102:1211-1216
12. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1442-1446
13. Joffe S, Ray T, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104:419-427
14. Lofland JH, Touch SM, O'Connor JP, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther. 2000;22:1357-1369
15. Farina D, Rodriguez S, Bauer G, et al. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatr Infect Dis J. 2002;21:287-291
16. Marchetti A, Lau H, Magar R, Wang L, Devercelli G. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther. 1999;21:752-766
17. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, MA: Little, Brown and Company, 1987
18. Anderson RM, McCutcheon A, Aday LA, Chiu GY, Bell R. Exploring dimensions of access to medical care. Health Serv Res. 1983;18:49-74
19. Aday LA, Anderson R. A framework for the study of access to medical care. Health Serv Res. 1974;9:208-220
20. Viswanathan M, King V, Bordley C, et al. Management of bronchiolitis in infants and children. Evidence Report/Technology Assessment No. 69 (Prepared by RTI International-University of North Carolina at Chapel Hill Evidence-Based Practice Center under Contract No. 290-97-0011). Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2003 (AHRQ Publication No. 03-E014)
21. Kraemer HC, Thiemann S. How Many Subjects? Statistical Power Analysis in Research. Newbury Park, CA: Sage Publications; 1987
22. Schlesselman JJ. Sample size requirements in cohort and case-control studies of disease. Am J Epidemiol. 1974;99:381-384
23. Gujarati DN. Basic Econometrics. 2nd ed. New York, NY: McGraw-Hill Book Company; 1988
24. Kennedy P. A Guide to Econometrics. 2nd ed. Cambridge, MA: MIT Press; 1985
25. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501-1507
26. Fonseca CB, Grisi S. Bronchiolitis, respiratory syncytial virus, and recurrent wheezing: what is the relationship? Rev Hosp Clin Fac Med Sao Paulo. 2003;58:39-48
27. Division of Public Health, Department of Health and Human Services, State Center for Health Statistics, North Carolina. North Carolina Health Statistics Pocket Guide - 2001. Raleigh, NC: Division of Public Health, Department of Health and Human Services, State Center for Health Statistics; 2001
28. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Munson ML. Division of Vital Statistics. Births: final data for 2002. Nat Vital Stat Rep. 2003;52
29. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J. 2003;22:483-489
30. Boyd DJ. The bursting state fiscal bubble and state Medicaid budgets. Health Aff. 2003;22:46-61
31. Boccuti C, Moon M. Comparing Medicare and private insurers: growth rates in spending over three decades. Health Aff. 2003;22:230-237